24 April 2024
Baker McKenzie advises CureVac to enter strategic collaboration with MD Anderson to develop novel cancer vaccines
Advising firms
Deal team
5 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Julia Schieber Lead | Baker McKenzie | Partner | healthcare and life sciences | Not stated |
| Randall Sunberg | Baker McKenzie | Partner | transactions | New York |
| Heiko E. Burrow | Baker McKenzie | Of counsel | IP | Dallas |
| Nadine Charrière | Baker McKenzie | Associate | IP | Zurich |
| Paula Ulmi | Baker McKenzie | Trainee | Not stated | Zurich |
2 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- CureVac N.V.Joint venture party
- Counterparties
- University of Texas MD Anderson Cancer Center (Joint venture party)